Federated Hermes Inc. Sells 15,544 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Federated Hermes Inc. lowered its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 75.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,000 shares of the company’s stock after selling 15,544 shares during the quarter. Federated Hermes Inc.’s holdings in Mirum Pharmaceuticals were worth $148,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. China Universal Asset Management Co. Ltd. increased its holdings in Mirum Pharmaceuticals by 98.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company’s stock valued at $31,000 after purchasing an additional 488 shares during the last quarter. Los Angeles Capital Management LLC increased its stake in shares of Mirum Pharmaceuticals by 1.2% in the 3rd quarter. Los Angeles Capital Management LLC now owns 42,444 shares of the company’s stock valued at $1,341,000 after acquiring an additional 494 shares during the last quarter. Swiss National Bank increased its stake in shares of Mirum Pharmaceuticals by 1.3% in the 3rd quarter. Swiss National Bank now owns 54,400 shares of the company’s stock valued at $1,719,000 after acquiring an additional 700 shares during the last quarter. Knights of Columbus Asset Advisors LLC boosted its stake in Mirum Pharmaceuticals by 1.4% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 57,871 shares of the company’s stock worth $1,829,000 after acquiring an additional 817 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its stake in Mirum Pharmaceuticals by 5.3% during the 3rd quarter. Janney Montgomery Scott LLC now owns 18,925 shares of the company’s stock worth $598,000 after acquiring an additional 950 shares during the last quarter.

Insider Transactions at Mirum Pharmaceuticals

In related news, COO Peter Radovich sold 4,303 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $25.80, for a total value of $111,017.40. Following the sale, the chief operating officer now owns 29,013 shares of the company’s stock, valued at $748,535.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Mirum Pharmaceuticals news, COO Peter Radovich sold 4,303 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $25.80, for a total transaction of $111,017.40. Following the transaction, the chief operating officer now owns 29,013 shares of the company’s stock, valued at approximately $748,535.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Eric Bjerkholt bought 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The stock was purchased at an average cost of $24.80 per share, with a total value of $49,600.00. Following the completion of the purchase, the chief financial officer now directly owns 14,000 shares of the company’s stock, valued at approximately $347,200. The disclosure for this purchase can be found here. Company insiders own 24.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on MIRM shares. HC Wainwright reiterated a “buy” rating and issued a $58.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, April 2nd. JMP Securities lifted their target price on Mirum Pharmaceuticals from $69.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, March 14th. SVB Leerink decreased their target price on Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a research note on Monday, March 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $35.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, February 29th. Finally, Stifel Nicolaus began coverage on Mirum Pharmaceuticals in a research report on Wednesday, April 17th. They issued a “buy” rating and a $48.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $51.70.

Mirum Pharmaceuticals Trading Up 0.9 %

NASDAQ MIRM opened at $25.84 on Monday. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $35.56. The company has a debt-to-equity ratio of 1.23, a quick ratio of 4.19 and a current ratio of 4.45. The stock’s 50 day moving average price is $26.12 and its two-hundred day moving average price is $28.18. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -6.51 and a beta of 1.13.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). The business had revenue of $69.55 million during the quarter, compared to the consensus estimate of $66.73 million. Mirum Pharmaceuticals had a negative return on equity of 66.24% and a negative net margin of 86.33%. As a group, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.34 earnings per share for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.